A phase I trial of dasatinib, a Src-family kinase Inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer

PURPOSE: We conducted a phase I study of dasatinib, an oral SRC-family tyrosine kinase inhibitor, in combination with paclitaxel and carboplatin in advanced and recurrent epithelial ovarian cancer. EXPERIMENTAL DESIGN: The primary objective was to determine the maximum tolerated dose (MTD). Secondar...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Secord, Angeles Alvarez, Teoh, Deanna K., Barry, William T., Yu, Miao, Broadwater, Gloria, Havrilesky, Laura J., Lee, Paula S., Berchuck, Andrew, Lancaster, Johnathan, Wenham, Robert M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2012
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3463759/
https://ncbi.nlm.nih.gov/pubmed/22837181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0507
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia